Macrophage-directed Therapies Summit 2021 - Overcoming Hostile Tumor Microenvironment With UI-102, a Pullulan Nanoparticle DDS-Encapsulated TLR7/8 Agonist That Actively Targets DCSIGN- Expressing M2-Like Tumor-Associated Macrophages

Overcoming Hostile Tumor Microenvironment With UI-102, a Pullulan Nanoparticle DDS-Encapsulated TLR7/8 Agonist That Actively Targets DCSIGN- Expressing M2-Like Tumor-Associated Macrophages

Time: 1:30 pm
day: Conference Day One

Details:

UI-102 significantly enhanced the efficacy of PD-1 and PD-L1 inhibitors in murine tumor models that are treatment resistant to checkpoint inhibitors
UI-102 promoted polarization of M2-like tumor-associated macrophages (TAMs) into M1 resulting in the conversion of refractory “cold” tumors onto “hot” ones and increased recruitment of CD8+ T cells and NK cells into tumors
Pullulan nanoparticle delivery to TAMs reduced the risk of cytokine release syndrome associates with TLR 7/8 agonists. First-in-human studies planned mid-2025